MG-566

MG-566 is a selective small molecule inhibitor of the Sec61 translocon, developed by Gate Bioscience. It is designed to selectively block the co-translational translocation and subsequent secretion of specific immunoglobulin light chain (LC) variable domains, particularly the IGLV1-44 variant, while sparing the majority of other Sec61 clients. In the context of AL amyloidosis, MG-566 induces a proteotoxic stress response and apoptosis specifically in plasma cells secreting the targeted light chain variant. This selective approach aims to reduce the circulating levels of toxic light chains and eliminate the diseased plasma cell clone, potentially offering a more targeted therapeutic strategy for AL amyloidosis patients with specific genetic profiles.